Search

everythinglearnresearchcommunity

for

Search:↓

IL-17 and certain immune cells are linked to more severe alopecia areata.

Treg dysfunction is linked to various autoimmune skin diseases, and understanding Treg properties is key for new treatments.

Foxp3 is crucial for regulatory T cell function, and targeting these cells may help treat immune disorders.

Enhancing regulatory T cells may help treat autoimmune diseases like alopecia areata.

Telocytes have potential in therapy and tissue regeneration, but challenges in identification and cultivation remain.

Hair follicles may help teach the immune system to tolerate new self-antigens, but this can sometimes cause hair loss.

Enhancing Tregs can protect against alopecia areata.

Fetal skin has unique immune cells different from adult skin.

Thymic transplantation normalized some T-cells but not others, maintaining immune function.

Innate lymphoid cells type 1 may contribute to alopecia areata by damaging hair follicles.

Increased regulatory T cell activity may lead to better outcomes in acute diffuse and total alopecia.

Thymic mesenchymal cells have unique gene expression that supports their specific functions in the thymus.

Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.

IL-17 plays a key role in severe hair loss in chronic alopecia areata.

Vδ1+ T-cells in the skin contribute to hair loss in alopecia areata and could be targeted for treatment.

γδTregs may help treat autoimmune diseases like alopecia areata by promoting hair regrowth and reducing immune attacks.

Hair follicle-derived IL-7 and IL-15 are crucial for maintaining skin-resident memory T cells and could be targeted for treating skin diseases and lymphoma.

HTLV-1-associated lichenoid dermatitis (HALD) is linked to an immune response against HTLV-1-infected cells.

Targeting Vδ1+T-cells may help treat alopecia areata.

Immunotherapies for non-small cell lung cancer show promise in improving treatment and reducing side effects.

Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.

CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.

Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.

A specific group of immune and skin cells may cause chronic inflammation in atopic dermatitis.

Treg cell-based therapies might help treat hair loss from alopecia areata, but more research is needed to confirm safety and effectiveness.

Super-enhancers control CD25 expression in specific cell types, affecting immune function.

Targeting CD200 could be a new treatment for rheumatoid arthritis.

Skin's Regulatory T cells are crucial for maintaining skin health and could be targeted to treat immune-related skin diseases and cancer.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

ILC1-like cells can cause alopecia areata by affecting hair follicles.